Logo-ijhpm
Int J Health Policy Manag. 2022;11(12): 2842-2859. doi: 10.34172/ijhpm.2022.6575
PMID: 35297231        PMCID: PMC10105170

Original Article

Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe

Piotr Ozieranski 1 * ORCID, Luc Martinon 2, Pierre-Alain Jachiet 2, Shai Mulinari 3 ORCID

Cited by CrossRef:

1- Larkin J, Mulinari S, Ozieranski P, Lynch K, Fahey T, Ozaki A, Moriarty F. Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: An observational study. Health Policy and Technology. 2024;13(2):100865 [Crossref]
2- Mulinari S, Pashley D, Ozieranski P. Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark. Health Policy. 2022;126(12):1256 [Crossref]
3- Ozieranski P, Saito H, Rickard E, Mulinari S, Ozaki A. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Global Health. 2023;19(1) [Crossref]
4- Mulinari S, Ozieranski P. Unethical pharmaceutical marketing: a common problem requiring collective responsibility. BMJ. 2023;:e076173 [Crossref]
5- Ozieranski P, Mulinari S. Broken beyond repair: self regulation of industry payments to clinicians and hospitals. BMJ. 2024;:q1559 [Crossref]